Clinical pharmacokinetics and selective pharmacodynamics of new angiotensin converting enzyme inhibitors: An update

Clinical Pharmacokinetics

Volumn 41, Issue 3, 2002, Pages 207-224

  Song, J C ^a,b   White, C M ^a,b  

^a HARTFORD HOSPITAL   (United States)

^b UNIVERSITY OF CONNECTICUT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENAZEPRIL; BENAZEPRILAT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CAPTOPRIL; CILAZAPRIL; CILAZAPRILAT; DELAPRIL; DELAPRIL 5 HYDROXYDIACID; DELAPRILAT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; FOSINOPRIL; FOSINOPRILAT; IMIDAPRIL; LISINOPRIL; MOEXIPRIL; PENTOPRIL; PENTOPRILAT; PERINDOPRIL; PERINDOPRILAT; QUINAPRIL; QUINAPRILAT; RAMIPRIL; SPIRAPRIL; TEMOCAPRIL; TRANDOLAPRIL; UNCLASSIFIED DRUG; UNINDEXED DRUG; WARFARIN;

AGE; AREA UNDER THE CURVE; CLINICAL TRIAL; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DISEASE ASSOCIATION; DOSE CALCULATION; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG ACTIVATION; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG COMPETITION; DRUG EFFICACY; DRUG PROTEIN BINDING; DRUG STRUCTURE; ENZYME INHIBITION; ESSENTIAL HYPERTENSION; FOOD AND DRUG ADMINISTRATION; FOOD DRUG INTERACTION; HEART FAILURE; HEART INFARCTION; HUMAN; KIDNEY FAILURE; LIVER FAILURE; MORBIDITY; MORTALITY; NONHUMAN; PRIORITY JOURNAL; REVIEW;

EID: 0036227555     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-200241030-00005     Document Type: Review

References (98)

1. Clinical pharmacokinetics of the newer ACE inhibitors: A review
2. Clinical pharmacokinetics of the angiotensin converting enzyme inhibitors: A review
3. Pharmacokinetics of the angiotensin-converting enzyme inhibitor, benazepril HCl (CGS 14824A), in healthy volunteers after single and repeated administration
4. Pharmacokinetics of benazeprilat after intravenous administration in healthy volunteers
5. The pharmacokinetics and bioavailability of cilazapril in normal man
6. Pharmacokinetics and depressor effect of delapril in patients with essential hypertension
7. Pharmacokinetics of a new angiotensin converting enzyme inhibitor (delapril) in patients with deteriorated kidney function and in normal control subjects
8. Disposition of fosinopril sodium in healthy subjects
9. Enalapril maleate and a lysine analogue (MK521): Disposition in man
10. Pharmacokinetics and pharmacodynamics of pentopril, a new angiotensin-converting-enzyme inhibitor in humans
11. Pharmacokinetics of pentopril in the elderly
12. Pentopril-cimetidine interaction caused by a reduction in hepatic blood flow
13. Effect of renal impairment on disposition of pentopril and its active metabolite
14. Influence of age on pharmacokinetics and pharmacodynamics of perindopril
15. Multiple dose cimetidine administration does not influence the single-dose pharmacokinetics of quinapril and its active metabolite (CI-928)
16. Pharmacokinetics of the ACE-inhibitor quinapril in young and elderly volunteers
17. Pharmacokinetics and biotransformation of 2-(N-((S)-1-ethoxycarboxyl-3-phenylpropyl)-L-alanyl)-(1S, 3S, 5S)-2-azabicyclo (3.3.0) octane-3-carboxylic acid (Hoe 498) in rat, dog, and man
18. Pharmacokinetics and pharmacodynamics of a novel orally active angiotensin converting enzyme inhibitor (Hoe 498) in healthy subjects
19. Pharmacokinetics, converting enzyme inhibition and peripheral arterial haemodynamics of ramipril in healthy volunteers
20. Pharmacokinetics of ramipril in the elderly
21. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS)
22. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure
23. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure
24. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure
25. Results of the ATLAS Study. High or low doses of ACE inhibitors for heart failure?
26. GISSI-3: Effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction
27. ISIS-4: A randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58 050 patients with suspected acute myocardial infarction
28. Oral captopril versus placebo among 13 634 patients with suspected acute myocardial infarction: Interim report from the Chinese Cardiac Study (CCS-1)
29. Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction. Results of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II)
30. Indications for ACE inhibitors in the early treatment of acute myocardial infarction: Systematic overview of individual data from 100,000 patients in randomized trials
31. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the Survival and Ventricular Enlargement trial
32. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure
33. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction
34. The effect of angiotensin-converting enzyme inhibition on diabetic nephropathy
35. Prevention of diabetic nephropathy with enalapril in normotensive diabetics with microalbuminuria
36. Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria
37. Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients
38. Some problems with antihypertensive drug studies in the context of the new guidelines
39. Losartan potassium: A review of its pharmacology, clinical efficacy, and tolerability in the management of hypertension
40. A new class of antihypertensive therapy: Angiotensin II antagonists
41. Vasoactive peptides
42. Pharmacologic, pharmacokinetic, and therapeutic differences among ACE inhibitors
43. Moexipril, a new angiotensin-converting enzyme (ACE) inhibitor: Pharmacological characterization and comparison with enalapril
44. Differential effects of oral trandolapril and enalapril on rat tissue angiotensin converting enzyme
45. Dose-finding study of imidapril, a novel angiotensin converting enzyme inhibitor, in patients with stable chronic heart failure
46. Value of different clinical and biochemical correlates to assess angiotensin converting enzyme inhibition
47. Tissue renin-angiotensin-systems: Fact or fiction?
48. Pharmacokinetics of imidapril and its active metabolite imidaprilat following single dose and during steady state in patients with chronic renal failure
49. Value of different clinical and biochemical correlates to assess angiotensin converting enzyme inhibition
50. Angiotensin-converting enzyme in rat brain and extraneural tissues visualized by quantitative autoradiography using 3H-trandolaprilate
51. Pharmacologic, metabolic, and toxicologic profile of spirapril (SCH 33844), a new angiotensin converting inhibitor
52. Pharmacological and toxicological studies of the new angiotensin converting enzyme inhibitor moexipril hydrochloride
53. Trandolapril: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in essential hypertension
54. Pharmacokinetics and pharmacodynamics of trandolapril after repeated administration of 2mg to young and elderly patients with mild-to-moderate hypertension
55. Angiotensin-converting enzyme inhibition, anti-hypertensive activity and hemodynamic profile of trandolapril (RU 44570)
56. Trandolapril: Pharmacokinetics of single oral doses in healthy male volunteers
57. Pharmacokinetics and pharmacodynamics of trandolapril after repeated administration of 2mg to patients with chronic renal failure and healthy control subjects
58. Pharmacology and clinical use of the new ACE-inhibitor moexipril
59. Pharmacokinetics and ACE-inhibition of the new ACE-inhibitor moexipril: Is coadministration with food of clinical relevance?
60. Spirapril: Pharmacokinetic properties and drug interactions
61. Pharmacokinetics of spirapril and spiraprilat in patients with chronic renal failure
62. Efficacy and safety of spirapril in mild-to-moderate hypertension
63. Single dose and steady state pharmacokinetics of temocapril and temocaprilat in young and elderly hypertensive patients
64. Single dose and steady state pharmacokinetics and pharmacodynamics of the ACE-inhibitor imidapril in hypertensive patients
65. Multiple doses of trandolapril do not affect warfarin pharmacodynamics
66. Indomethacin does not attenuate the hypotensive effect of trandolapril
67. Lack of a pharmacokinetic interaction between moexipril and hydrochlorothiazide
68. Moexipril does not alter the pharmacokinetics or pharmacodynamics of warfarin
69. Digoxin pharmacokinetics and spirapril, a new ACE inhibitor
70. Single-dose pharmacokinetics of temocapril and temocapril diacid in subjects with varying degrees of renal impairment
71. Pharmacokinetics of temocapril and temocaprilat after 14 once-daily oral doses of temocapril in hypertensive patients with varying degrees of renal impairment
72. Study on pharmacokinetics of a new biliary excreted oral angiotensin converting enzyme inhibitor, temocapril (CS-622) in humans
73. Fosinopril: Clinical pharmacokinetics and clinical potential
74. Pharmacokinetics of imidapril and its active metabolite imidaprilat following single dose and during steady state in patients with impaired liver function
75. Pharmacokinetic and pharmacodynamic interaction trial after repeated oral doses of imidapril and digoxin in healthy volunteers
76. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure
77. Effect of angiotensin-converting enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: The Captopril Prevention Project (CAPPP) randomised trial
78. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly study, ELITE)
79. Angiotensin-converting-enzyme inhibition in heart failure or after myocardial infarction
80. Vitamin E supplementation and cardiovascular events in high-risk patients
81. Role of angiotensin-converting-enzyme inhibition in patients with renal disease
82. Dose-response relationships with antihypertensive drugs
83. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: A comparative study of the efficacy and safety against amlodipine
84. Chronic dose-response curve of enalapril in essential hypertensives. An Italian multicenter study
85. Lisinopril dose-response relationship in essential hypertension
86. Once-daily fosinopril in the treatment of hypertension
87. Antihypertensive effect of fosinopril, a new angiotensin converting enzyme inhibitor: Findings of the fosinopril study group II
88. Perindopril as monotherapy in hypertension: A multicenter comparison of two dosing regimens
89. The antihypertensive properties of the angiotensin converting enzyme inhibitor moexipril given alone or in combination with a low dose of a diuretic
90. Dose finding studies with imidapril - A new ACE inhibitor
91. Clinical pharmacology of quinapril in healthy volunteers and in patients with hypertension and congestive heart failure
92. Diurnal blood pressure in patients with mild-to-moderate hypertension treated with once-daily benazepril
93. Crossover design for the dose determination of an angiotensin converting enzyme inhibitor in hypertension
94. Use of crossover trials to obtain antihypertensive dose-response curves and to study combination therapy during the development of benazepril
95. FDA guidelines on trough: Peak ratios in the evaluation of antihypertensive agents
96. Trough/peak ratios of once-daily angiotensin converting enzyme inhibitors and calcium antagonists
97. Determining the trough-to-peak ratio in parallel-group trials